Keywords
Acne vulgaris tazarotene , adapelene
This article is included in the Datta Meghe Institute of Higher Education and Research collection.
Background: Acne is an extremely common skin condition, which has a major social and psychological impact on young patients. Retinoids have been a mainstay of anti-acne therapy. Older generation agents are slowly replaced by newer generation ones like tazarotene and adapalene as they exhibit lower toxicologic risk and less side effects and they effectively reduce the comedones and inflammatory lesions. This study throws light on effectiveness of topical Adapalene gel- 0.1% and Tazarotene gel-0.05% in order to find out a suitable option with lesser side effects for acne patients.
Methods: After clearance from the institutional ethics committee, acne patients aged >12-35 years at the outpatient area of the Dermatology department, AVBRH, Jawaharlal Nehru Medical College, Sawangi, Wardha, were enrolled in the study. Patients will be randomly assigned in two groups wherein group A will be prescribed Tazarotene-0.05% gel and group B prescribed Adapalene-0.1% gel along with Tab Azithromycin-500mg thrice weekly for 12 weeks for both groups. Patients will be clinically assessed on every 4th, 8th and 12th week. Global acne score system will be applied at enrolment and at each subsequent follow-up for evaluation.
Acne vulgaris tazarotene , adapelene
The development of papules which are erythematous pustules and sometimes nodules and pseudocysts all often occur in acne patients.1 More than 85% of teenagers are affected, making it a very common skin disorder in younger population.2 The main pathogenic mechanisms include propionibacterium acnes microbiological colonisation of pilosebaceous units, which promotes perifollicular inflammation, oil gland secretion stimulation by androgens, abnormal infundibular epithelial keratinization, and hyperkeratinization.3 When it comes to ultrastructure, it can be shown that follicular keratinocytes in comedones contain more desmosomes and tonofilaments. A pilo-sebaceous follicular disorder with persistent inflammation that can affect young adults and has negative social and psychological outcomes. Regardless of colour or ethnicity, everyone between the ages of 12 and 17 must have occasionally come into contact with a white head or a black head. Therefore, it is therefore crucial to manage acne at the earliest possible stage.4
Since they have so many different mechanisms of action, retinoids have been a crucial part of anti-acne therapy. They successfully lessen the inflammatory lesions and comedones. Newer generation medications like Tazarotene and Adapalene are gradually replacing the long-established Tretinoin and Isotretinoin. These are selective for a subset of retinoic acid receptors, also unlike Tretinoin, that exhibits lower toxicologic risk and results in less side effects.5 This study focuses primarily on the effectiveness of Adapalene gel of 0.1% applied topically and Tazarotene gel of 0.05% applied topically in order to find a modality of treatment for facial acne vulgaris that is more effective because very few clinical trials based on the basis of effectivity and toleranace of tazarotene gel of 0.05% to that of adapelene gel of 0.1% have been performed.
One of the skin conditions that causes emotional trauma, feelings of inferiority, and insecurity, acne is one of the skin conditions that today’s teenagers worry about the most. Consequently, it is now important to manage acne at an early stage.3
A retinoic acid receptor-specific drug is tazarotene. It inhibits keratinocyte growth, differentiation, and markers of inflammation. The drug also increases the expression of three distinct genes called TIG-1, TIG-2, and TIG-3 are the three genes that may have an antiproliferative effect. Instead of an indirect effect linked to the improvement of disease, the result of tazarotene on these indicators is likely an influence on expression of genes.6 Retinoids are frequently used as a last resort to cure acne, but they also have a few negative effects. Finding a retinoid with fewer side effects is therefore necessary and preferred. Additionally, relatively few research has been done in India regarding the effectiveness of 0.05% tazarotene. Therefore, it is crucial to create a study that focuses on comapritive study between these two. Also this study will help us infer to which topical formulations are effective for acne treatment wherein oral medication need not be given or are contraindicated.
The aim of this study is the comparison of the effectivity of tazarotene gel of 0.05% to that of adapelene gel of 0.1% in treating acne vulgaris on the face.
The objectives are as follows:
1) To research how well topical Tazarotene 0.05% gel works to treat acne vulgaris on the face.
2) To research the effectiveness tazarotene gel of 0.05% to that of adapelene gel of 0.1%.
3) To evaluate how well Adapalene gel of 0.1% and topical Tazarotene gel of 0.05% treat acne on the face.
4) To investigate the multiple adverse effects of tazarotene gel of 0.05% and adapalene gel of 0.1%.
The study will be a randomized, single blinded, parallel group, case controlled trial. Patients suffering from acne vulgaris patients with age >12-35 years attending the the outpatient unit of the Department of Dermatology, AVBRH Sawangi Meghe, Wardha. The study period is two years; from June 2022 to September 2024.
Prevalance of acne in group of following age of 12-35 years is a range of 75-80%
Prevalance of acne vulgaris in an age group of 12-35 years is a range of 75-80%
With value of significance 0.05
A 80.27% reduction in acne vulgaris lesions was shown with the usage of 0.1% adapelene.
B 53.13% reduction in acne vulgaris lesions was shown with the usage of 0.1% tazorotene.7
Sample size in each group: 73
Total sample size: 146
Patients who have been clinically diagnosed with acne vulgaris with age >12-35 years who would be registered from June 2022 to September 2024 at the OPD of department of Dermatology, JNMC Wardha, Sawangi Wardha with clearance from the institutional ethics committee (ECR/440/Inst/MH/2013/RR-2019). All patients who choose to participate voluntarily will be asked for written informed consent. a thorough background containing information on your age, gender, educational level, socioeconomic standing, employment, marital status, occupation, past drug use, and the length of the application will be taken.
Patients will be randomized into one of two groups (Group A and Group B) by straight forward randomization by computer-generated numbers. Group A will be prescribed Tazarotene 0.05% gel along with Tab Azee 500 mg thrice weekly for 12 weeks and Group B will be prescribed Adapalene 0.1% gel along with Tab Azee 500 mg thrice weekly.
For assessment of improvement a system of scoring will be called Global Acne Scoring (Table 1) be used when the patient is being enrolled and also with every consecutive follow-up.8
Location | Grade |
---|---|
Forehead | 2 |
Right cheek | 2 |
Left cheek | 2 |
Nose | 1 |
Chin | 1 |
Chest & upper back | 3 |
Global acne scores:
0 = NONE
1-18 = MILD
19-30 = MODERATE
31-38 = SEVERE
>39 = VERY SEVERE
Total counts of papules, comedones, nodules, pustules, at the time of the first visit and then in every consecutive follow-up will be noted down. It will also be mentioned that retinoids have negative effects, including dryness, erythema, acne flare-ups, and itching. The method application that will be explained to the patient will include the application of tazarotene on the acne lesions overnight on a properly washed clean face. A routine moisturizer will be prescribed to a patient to combat the dryness that may be a side effect.
The study will have a total 12 weeks (3 months) follow-up duration. The patient will be called for follow-up every fortnight during this tenure.
Total clearance of lesions, improvement in numbers of counts of comedones, papules, pustules, and nodules, improvement in global acne scoring, side effects i.e. dryness, erythema, itching, and flare-up of acne will be studied. To observe the improvement in the acne of patients based on Global Acne Scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, and the side effects that arise with the usage of 0.05% tazarotene and 0.1% adapalene.
For our statistical analysis, we will apply the necessary parametric and non-parametric tests. The SPSS 16.0 version will be used to analyse the data collected. For the comparison of qualitative data between two variables, descriptive statistics like proportion, mean, and standard deviation will be employed, while the chi square test and other statistics that are inferential like chi square test will be employed. Using independent T tests (unpaired t tests) and paired t tests, quantitative data between two variables will be compared before and after. The 95% level will act as the fixed upper bound for significance if the p-value is less than 0.05.
A study determined that tazarotene 0.1% cream and tretinoin 0.05% cream are individually effective and tolerable in the treatment of mild to moderate acne vulgaris. Patients were alloted in a group of two, Group A and Group B, based on the number of comedones.9
Bershad et al. determined that Tazarotene shows improvement patients of acne vulgaris when used topically. A safe and efficient topical treatment for acne appears to be topical tazarotene with the exception of ovulating females, in whom proper safety precautions should be taken.10
Acne on face was treated with tazarotene gel of 01% and adapelene gel of 0.1%. in a study in 106 acne patients. Every patient had a thorough clinical examination. The efficiency of daily use of tazarotene gel of 0.05% and adapalene gel of 0.1% for the treatment of facial acne vulgaris were evaluated in a multicenter, double-blind, randomised comparison research.11
GF Webster and colleagues found that the treatment with tazarotene gel has been associated with considerably higher rates of success when compared to adapalene as well as significantly lower levels of total disease severity, lesion count of non inflammatory type and inflammatory type. In conclusion, tazarotene gel of 0.1% was more effective than adapalene gel of 0.1% and was also a more cost-effective treatment.12 Our findings will be in line with the said research.
This is a randomised controlled study wherein we compare the efficacy of 0.05% tazarotene gel to 0.1% adapelene gel in grade I to III patients with acne vulgaris. This study’s significance lies in the addition of newer topical medications and the examination of the interaction between tazarotene and other systemic medications. Also to study the effect of tazarotene with combinations with other topical agents that will help us find better effective modality for patient of acne on the face.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Clinical dermatology, Cosmetic dermatology, Skin cancer, Skin Surgery, Sexually Transmitted Infection
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
No
Are sufficient details of the methods provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
Not applicable
References
1. Valente Duarte de Sousa IC: Guidance for the pharmacological management of acne vulgaris.Expert Opin Pharmacother. 2022; 23 (1): 49-62 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Acne and hair diseases
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 15 Nov 23 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)